Retatrutide's TRIUMPH-4 Phase 3 results, announced in December 2025, reported 28.7% mean body weight reduction at 68 weeks at the 12 mg dose. This is the largest weight loss ever achieved by any pharmaceutical agent in a Phase 3 trial, surpassing tirzepatide's 22.5% (SURMOUNT-1) and semaglutide's 14.9% (STEP-1).
The number matters because it redraws the competitive landscape. When semaglutide launched, double-digit percentage weight loss from a medication was unprecedented. Tirzepatide moved the ceiling past 20%. Retatrutide has now pushed it approaching 30%. Each step represents a pharmacologically distinct mechanism: GLP-1 alone, then GLP-1 plus GIP, then GLP-1 plus GIP plus glucagon.
Retatrutide is the first triple agonist to reach Phase 3: it simultaneously activates the GLP-1, GIP, and glucagon receptors. Semaglutide activates GLP-1 alone. Tirzepatide activates GLP-1 and GIP. The glucagon receptor component is the mechanistic differentiator, and it contributes two effects that the other agents lack.
First, glucagon receptor activation increases basal energy expenditure through thermogenesis in brown adipose tissue. This is an additive weight loss mechanism on top of the appetite suppression driven by GLP-1. Second, glucagon drives hepatic fat oxidation through pathways including PCSK9-mediated LDL receptor degradation, which may explain why retatrutide produces substantial liver fat clearance.
The TRIUMPH-4 secondary endpoints support this: reductions in non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure (14.0 mmHg reduction at the highest dose). These are clinically meaningful cardiometabolic improvements, though a dedicated cardiovascular outcomes trial has not yet reported.
TRIUMPH-4 is a weight loss and metabolic endpoints trial, not a cardiovascular outcomes trial. The 28.7% weight loss number is real, but the question that matters most for regulatory positioning and clinical adoption is whether this translates to reduced cardiovascular events. Semaglutide's SELECT trial (n=17,604) demonstrated a 20% MACE reduction. Until retatrutide produces equivalent outcomes data, the weight loss magnitude alone does not establish clinical superiority for the outcome that matters most.
The TRIUMPH cardiovascular outcomes trial is ongoing. Results are not expected before 2027 at the earliest.
The weight loss ranking among approved and late-stage agents is now clear: retatrutide (28.7%) > tirzepatide (22.5%) > semaglutide (14.9%). Survodutide (dual GLP-1/glucagon, Boehringer Ingelheim) and mazdutide (dual GLP-1/glucagon, Innovent/Lilly) are also in Phase 3 with their own glucagon-inclusive mechanisms. Cagrilintide (amylin analogue, Novo Nordisk) takes a mechanistically orthogonal approach through the amylin/calcitonin pathway.
The practical question for the field is not which agent produces the most weight loss in a controlled trial. It is which agent produces the best risk-adjusted outcomes at a tolerable side effect profile for a given patient. GI tolerability, cardiovascular outcomes, cost, and access will determine clinical adoption far more than headline weight loss percentages.
Retatrutide is not available outside of clinical trials as of April 2026. It is not FDA-approved. It is not available through compounding pharmacies. ClinicalTrials.gov lists active TRIUMPH trial sites for those interested in enrollment.
Full evidence profiles for all compounds mentioned are available in the database: Retatrutide, Semaglutide, Tirzepatide, Survodutide, Mazdutide, and Cagrilintide.
28.7% mean weight loss is a genuine pharmacological achievement. The triple agonist mechanism is scientifically compelling and the Phase 3 data are methodologically robust. But the drug is not yet approved, the cardiovascular outcomes data do not yet exist, and the tolerability at the highest doses requires long-term safety data that only post-marketing surveillance will provide. Watch this space.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use